A Phase III Randomized, Open Label, Parallel Group Comparative Clinical Trial to evaluate the efficacy, safetyand tolerability of AlflutopÃ?Â®, solution for injection, administered intramuscularly in subjects withosteoarthritis of knee joints.

Biotehnos Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

阶段: 3 期
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Signed Patient Information Sheet and Informed Consent Form to participate in the study.
•2. Men and women aged 40 to 75 years (inclusive).
•3. Diagnosis of osteoarthritis of the knee joint established in accordance with the classification criteria of the American College of Rheumatology (ACR) and with X-ray signs of grade II or III according to the Kellgren-Lawrence classification.
•4. Pain during walking in target knee joint according to VAS > 40 mm (moderate or severe pain when walking).
•Patients with bilateral osteoarthritis of knee joints can be included in the study, but data on efficacy and safety must be collected for the most painful knee joint (target knee). According to VAS, the level of pain in the contralateral knee joint must be less than in the target knee joint ( <40 mm), if the pain intensity is the same in both joints, joint with a higher grade according to Kellgren-Lawrence classification is chosen. If both knee joints are equally painful and have the same stage according to the Kellgren-Lawrence classification, then the knee joint is chosen at the discretion of the investigator.
•5. Need of daily/ long-term use of NSAIDs (at least 30 days) over the past three months.
•6. Consent of patients, including men and women with childbearing potential (who have not undergone surgical sterilization or who have been in menopause less than 2 years), to use adequate contraception methods during the entire study and 3 months after the end of therapy. Adequate contraceptive methods include a condom or diaphragm

排除标准

•1. Concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis etc.)
•2. Significant (requiring surgical treatment) valgus or varus deformity of the knee joint, ligamentous laxity, or destruction of the meniscus.
•3. Concomitant osteoarthritis of the hip and/or ankle joints, of severe grade, which may make it difficult to assess the effectiveness or pain in the knee joint.
•4. History of septic arthritis of any joint or suspected subacute infectious inflammation in the target joint.
•5. Surgical treatment of a targeted knee in history.
•6. Planned surgery on any joint of the lower extremities during the study.
•7. Lymphovenous insufficiency of the lower limbs, grade III.
•8. Diseases and concomitant conditions affecting the structure and density of bone tissue (hyperparathyroid osteodystrophy, malabsorption syndrome, osteomalacia, osteogenesis imperfecta, etc.).
•9. The following abnormalities of laboratory parameters:
•Complete blood count:Hemoglobin: <10.0 g/dL
•Liver function:Total bilirubin: >2.0 Ã?â?? UNL
•AST or ALT: >2.5 Ã?â?? UNL
•Kidney function:GFR (Cockcroft-Gault formula): <60 mL/min
•10. Current or 12 months prior to screening severe cardiovascular diseases, including: NYHA Class III or IV chronic heart failure, clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction, heart and coronary vessel surgery, significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg, pulmonary embolism or deep vein thrombosis.
•11. Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus (HbA1c > 10.5 %, fasting plasma glucose >270 mg/dl at screening or episodes of severe hypoglycemia 1 month prior to screening);
•12. Subjects with BMI Ã¢â?°Â¥ 40 kg/m2
•13. Severe diseases of the central nervous system, including seizures in history or conditions that may lead to their development; stroke or transient ischemic attack within 12 months prior to screening; head injuries or loss of consciousness within 12 months prior to screening; a brain tumor.
•14. Diseases manifested by increased bleeding (hemorrhagic diathesis, hemophilia, thrombocytopenia, etc.), or conditions with a high risk of bleeding.
•15. Significant uncontrolled concomitant disease, such as neurological, renal, hepatic, endocrine and gastrointestinal which according to the Investigator, could prevent the patient from participating in the study.
•16. Participation in other clinical studies or administration of investigational products within 4 weeks prior to screening.
•17. HIV, active viral (hepatitis B and C) or a cirrhotic liver disease in medical history.
•18. Malignancies within the last 5 years (except for basal cell carcinoma of the skin and cervical cancer in situ that had undergone surgical removal or treatment).
•19. Drug or alcohol abuse at the time of screening or in the past which, in the opinion of the Investigator, makes the patient un

研究者

发起方

Biotehnos Private Limited

相似试验

进行中（未招募）

1 期

EUCTR2020-004085-19-DEargenx BV110

进行中（未招募）

1 期

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersGeneralized Myasthenia Gravis

EUCTR2020-004085-19-BEargenx BV76

进行中（未招募）

1 期

EUCTR2020-004085-19-HUargenx BV110

进行中（未招募）

1 期

EUCTR2020-004085-19-NLargenx BV76

已完成

3 期

A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC with Multiple Intravenous Infusions of Efgartigimod in Patients with Generalized Myasthenia Gravis (ADAPT)Disease of the neuro muscular junctionSerious muscle weakness1000381610029317

NL-OMON51130argenx BV2